A Phase 3 interventional study of GnRH antagonist and MPA in Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation and Polycystic Ovarian Syndrome, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Not yet recruiting. Open to female participants aged 20 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:
Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.
The primary outcome is the euploidy rate of blastocysts.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
This study's planned enrollment of 204 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Drug: GnRH antagonist
Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.
Drug: MPA
GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Also known as: Cetrorelix
oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
euploidy rate
euploidy rate of blastocysts
Time frame: 1 month after oocyte retrieval
live birth rate
deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer
Time frame: 1 year after embryo transfer
cumulative live birth rate
cumulative live birth within 6 months of randomization
Time frame: 1 year after embryo transfer
ongoing pregnancy
a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer
Time frame: 12 weeks' gestation
number of oocytes retrieved
number of oocytes retrieved
Time frame: 1 day after oocyte retrieval
OHSS(ovarian hyperstimulation syndrome)
Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline. Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016).
Time frame: 1 month after ovarian stimulation
birthweight of newborns
birthweight of newborns
Time frame: 1 year after embryo transfer
No study locations are listed for this record.
Plan to share: Yes — Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available when beginning 3 months and ending 5 years following article publication.
Access criteria: To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with. Proposals should be sent to lihe198900@163.com.
Start is estimated for Jun 2027; primary completion for Dec 2028, 18 months later.
Of 26 non-industry phase 3 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 18 months is below that.
Counting every sponsor, half of 26 studies reached it within 28 months; a quarter within 11 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jun 2026 → Jun 2027 and primary completion Dec 2027 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medroxyprogesterone Acetate
ShangHai Ji Ai Genetics & IVF Institute